MA30643B1 - 2-phenylindoles en tant qu'antagonistes du recepteur de la prostaglandine d2. - Google Patents
2-phenylindoles en tant qu'antagonistes du recepteur de la prostaglandine d2.Info
- Publication number
- MA30643B1 MA30643B1 MA31635A MA31635A MA30643B1 MA 30643 B1 MA30643 B1 MA 30643B1 MA 31635 A MA31635 A MA 31635A MA 31635 A MA31635 A MA 31635A MA 30643 B1 MA30643 B1 MA 30643B1
- Authority
- MA
- Morocco
- Prior art keywords
- disorders
- urticaria
- atopic dermatitis
- diseases
- systemic
- Prior art date
Links
- 102000009389 Prostaglandin D receptors Human genes 0.000 title 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 208000035475 disorder Diseases 0.000 abstract 3
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 208000003251 Pruritus Diseases 0.000 abstract 2
- 208000024780 Urticaria Diseases 0.000 abstract 2
- 201000008937 atopic dermatitis Diseases 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- KLLLJCACIRKBDT-UHFFFAOYSA-N 2-phenyl-1H-indole Chemical class N1C2=CC=CC=C2C=C1C1=CC=CC=C1 KLLLJCACIRKBDT-UHFFFAOYSA-N 0.000 abstract 1
- 206010002199 Anaphylactic shock Diseases 0.000 abstract 1
- 206010006482 Bronchospasm Diseases 0.000 abstract 1
- 208000002177 Cataract Diseases 0.000 abstract 1
- 206010008190 Cerebrovascular accident Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 208000004262 Food Hypersensitivity Diseases 0.000 abstract 1
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 abstract 1
- 101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 206010038848 Retinal detachment Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 201000008736 Systemic mastocytosis Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 208000002205 allergic conjunctivitis Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 208000003455 anaphylaxis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000024998 atopic conjunctivitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 230000007885 bronchoconstriction Effects 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000024711 extrinsic asthma Diseases 0.000 abstract 1
- 235000020932 food allergy Nutrition 0.000 abstract 1
- 210000003630 histaminocyte Anatomy 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 230000007803 itching Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000008423 pleurisy Diseases 0.000 abstract 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 abstract 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 abstract 1
- 230000004264 retinal detachment Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 238000006748 scratching Methods 0.000 abstract 1
- 230000002393 scratching effect Effects 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Abstract
La présente invention concerne des dérivés de 2-phényl-indole (A), leur synthèse, les compositions pharmaceutiques les contenant et leur application pharmaceutique au traitement d'un patient souffrant d'un trouble faisant intervenir PGD2, incluant sans y être limité les maladies allergiques (comme la rhinite allergique, la conjonctivite allergique, la dermatite atopique, l'asthme et les allergies alimentaires), la mastocytose systémique, les troubles accompagnés de l'activation systémique de mastocytes, le choc anaphylactique, la bronchoconstriction, la bronchite, l'eczéma, l'urticaire, les maladies accompagnées de démangeaisons (telles que la dermatite atopique et l'urticaire), les maladies (telles que la cataracte, le décollement rétinien, les inflammations, les infections et les troubles du sommeil) qui sont des conséquences au second degré d'un comportement de réaction à des démangeaisons (comme le fait de se gratter ou de se frapper), les inflammations, les bronchopneumopathies chroniques obstructives, les lésions de reperfusion ischémique, les accidents cérébrovasculaires, la polyarthrite rhumatoïde chronique, la pleurésie, la rectocolite hémorragique et les troubles similaires.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82029906P | 2006-07-25 | 2006-07-25 | |
| US82030106P | 2006-07-25 | 2006-07-25 | |
| US82030206P | 2006-07-25 | 2006-07-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA30643B1 true MA30643B1 (fr) | 2009-08-03 |
Family
ID=38610820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA31635A MA30643B1 (fr) | 2006-07-25 | 2009-02-13 | 2-phenylindoles en tant qu'antagonistes du recepteur de la prostaglandine d2. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20090176804A1 (fr) |
| EP (1) | EP2066628B1 (fr) |
| JP (1) | JP2009544721A (fr) |
| KR (1) | KR20090039735A (fr) |
| AR (1) | AR062051A1 (fr) |
| AT (1) | ATE485270T1 (fr) |
| AU (1) | AU2007276885A1 (fr) |
| BR (1) | BRPI0714554A2 (fr) |
| CA (1) | CA2659055A1 (fr) |
| CL (1) | CL2007002163A1 (fr) |
| CO (1) | CO6190511A2 (fr) |
| CR (1) | CR10577A (fr) |
| DE (1) | DE602007010010D1 (fr) |
| DK (1) | DK2066628T3 (fr) |
| EC (1) | ECSP099087A (fr) |
| GT (1) | GT200900016A (fr) |
| IL (1) | IL196587A0 (fr) |
| MA (1) | MA30643B1 (fr) |
| MX (1) | MX2009000830A (fr) |
| NO (1) | NO20090862L (fr) |
| PE (1) | PE20080549A1 (fr) |
| PT (1) | PT2066628E (fr) |
| TN (1) | TNSN08515A1 (fr) |
| TW (1) | TW200821286A (fr) |
| WO (1) | WO2008014186A1 (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009072576A1 (fr) * | 2007-12-04 | 2009-06-11 | Sapporo Breweries Limited | Stimulateur de la formation osseuse |
| RS52809B (sr) * | 2008-11-17 | 2013-10-31 | F. Hoffmann-La Roche Ag. | Naftilsirćetne kiseline |
| MX2012010820A (es) | 2010-03-22 | 2012-10-10 | Actelion Pharmaceuticals Ltd | Derivados de 3-(heteroaril-amino)-1, 2, 3, 4-tetrahidro-9h-carbazo l y sus uso como moduladores del receptor de prostaglandina d2. |
| WO2012140612A1 (fr) | 2011-04-14 | 2012-10-18 | Actelion Pharmaceuticals Ltd | Dérivés d'acide 7-(hétéroaryl-amino)-6,7,8,9-tétrahydropyrido[1,2-a]indolacétique et leur utilisation en tant que modulateurs du récepteur aux prostaglandines d2 |
| EP2912458B1 (fr) | 2012-10-24 | 2018-07-18 | NYU Winthrop Hospital | Biomarqueurs non-invasifs pour identifier les sujets à risque d'accouchement prématuré |
| JP2015089886A (ja) * | 2013-11-06 | 2015-05-11 | 国立大学法人名古屋大学 | 嵩高い置換基を有する化合物を用いた植物成長調整剤 |
| PH12016501764B1 (en) | 2014-03-17 | 2024-05-17 | Idorsia Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| WO2015140701A1 (fr) | 2014-03-18 | 2015-09-24 | Actelion Pharmaceuticals Ltd | Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2 |
| WO2017046125A1 (fr) | 2015-09-15 | 2017-03-23 | Actelion Pharmaceuticals Ltd | Formes cristallines |
| KR20200109293A (ko) | 2017-09-13 | 2020-09-22 | 프로제너티, 인크. | 자간전증 바이오마커 및 관련된 시스템 및 방법 |
| US11884645B2 (en) | 2018-03-02 | 2024-01-30 | Inflazome Limited | Sulfonyl acetamides as NLRP3 inhibitors |
| US12168653B2 (en) | 2018-03-02 | 2024-12-17 | Inflazome Limited | Sulfonamide derivates as NLRP3 inhibitors |
| EP3759090A1 (fr) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Nouveaux composés |
| US11834433B2 (en) | 2018-03-02 | 2023-12-05 | Inflazome Limited | Compounds |
| WO2019166632A1 (fr) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Nouveaux composés |
| CN112384497A (zh) | 2018-05-09 | 2021-02-19 | 格卢科克斯生物科技有限公司 | 具有选择性nox抑制活性的新型磺酰胺衍生物 |
| WO2021113710A1 (fr) | 2019-12-04 | 2021-06-10 | Progenity, Inc. | Évaluation de la prééclampsie à l'aide de dosages du facteur de croissance placentaire libre et dissocié |
| CN111333516B (zh) * | 2020-04-14 | 2022-09-06 | 国药集团化学试剂有限公司 | 一种2-氯-5-溴硝基苯的制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP2006000016A (es) * | 2005-01-26 | 2006-07-31 | Aventis Pharma Inc | 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2. |
-
2007
- 2007-07-20 KR KR1020097001687A patent/KR20090039735A/ko not_active Abandoned
- 2007-07-20 DE DE602007010010T patent/DE602007010010D1/de active Active
- 2007-07-20 WO PCT/US2007/073945 patent/WO2008014186A1/fr not_active Ceased
- 2007-07-20 EP EP07799729A patent/EP2066628B1/fr active Active
- 2007-07-20 MX MX2009000830A patent/MX2009000830A/es active IP Right Grant
- 2007-07-20 PT PT07799729T patent/PT2066628E/pt unknown
- 2007-07-20 CA CA002659055A patent/CA2659055A1/fr not_active Abandoned
- 2007-07-20 DK DK07799729.4T patent/DK2066628T3/da active
- 2007-07-20 BR BRPI0714554-3A patent/BRPI0714554A2/pt not_active IP Right Cessation
- 2007-07-20 JP JP2009521914A patent/JP2009544721A/ja not_active Abandoned
- 2007-07-20 AT AT07799729T patent/ATE485270T1/de active
- 2007-07-20 AU AU2007276885A patent/AU2007276885A1/en not_active Abandoned
- 2007-07-23 PE PE2007000951A patent/PE20080549A1/es not_active Application Discontinuation
- 2007-07-24 AR ARP070103291A patent/AR062051A1/es not_active Application Discontinuation
- 2007-07-24 CL CL200702163A patent/CL2007002163A1/es unknown
- 2007-07-25 TW TW096127005A patent/TW200821286A/zh unknown
-
2008
- 2008-12-12 TN TNP2008000515A patent/TNSN08515A1/en unknown
-
2009
- 2009-01-15 CO CO09002745A patent/CO6190511A2/es not_active Application Discontinuation
- 2009-01-19 IL IL196587A patent/IL196587A0/en unknown
- 2009-01-21 CR CR10577A patent/CR10577A/es not_active Application Discontinuation
- 2009-01-22 US US12/357,725 patent/US20090176804A1/en not_active Abandoned
- 2009-01-23 GT GT200900016A patent/GT200900016A/es unknown
- 2009-01-23 EC EC2009009087A patent/ECSP099087A/es unknown
- 2009-02-13 MA MA31635A patent/MA30643B1/fr unknown
- 2009-02-24 NO NO20090862A patent/NO20090862L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PE20080549A1 (es) | 2008-06-20 |
| ECSP099087A (es) | 2009-02-27 |
| CR10577A (es) | 2009-03-20 |
| WO2008014186A1 (fr) | 2008-01-31 |
| PT2066628E (pt) | 2010-12-31 |
| TNSN08515A1 (en) | 2010-04-14 |
| DE602007010010D1 (de) | 2010-12-02 |
| JP2009544721A (ja) | 2009-12-17 |
| CL2007002163A1 (es) | 2008-02-08 |
| EP2066628B1 (fr) | 2010-10-20 |
| BRPI0714554A2 (pt) | 2013-05-07 |
| KR20090039735A (ko) | 2009-04-22 |
| IL196587A0 (en) | 2009-11-18 |
| CA2659055A1 (fr) | 2008-01-31 |
| ATE485270T1 (de) | 2010-11-15 |
| TW200821286A (en) | 2008-05-16 |
| EP2066628A1 (fr) | 2009-06-10 |
| MX2009000830A (es) | 2009-02-03 |
| AU2007276885A1 (en) | 2008-01-31 |
| DK2066628T3 (da) | 2011-02-07 |
| CO6190511A2 (es) | 2010-08-19 |
| US20090176804A1 (en) | 2009-07-09 |
| GT200900016A (es) | 2010-10-13 |
| NO20090862L (no) | 2009-02-24 |
| AR062051A1 (es) | 2008-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA30409B1 (fr) | Amino-pyrimidine 2,6-substituee-4-mono-substituee en tant qu'antagoniste du recepteur de la prostaglandine d2. | |
| MA29259B1 (fr) | 2-phénylindoles en tant qu'antagonistes du récepteur de la prostaglandine d2 | |
| MA30005B1 (fr) | Sel dihydrogenophosphate d'un antagoniste du recepteur de la prostaglandine d2 | |
| BRPI0516482A (pt) | 2, 6-substituìda-4-monossubstituìda-amino-pirimidina como antagonistas receptor de prostaglandina d2 | |
| NO20090862L (no) | 2-fenyl-indoler som prostaglandin D2-reseptorantagonister | |
| JP2009503113A (ja) | サーチュイン調節因子としてのイミダゾピリジン誘導体 | |
| ATE516277T1 (de) | Carbonsäureverbindungen und arzneimittel, die diese verbindungen als wirkstoffe enthalten | |
| NO20024281L (no) | Indolderivater, fremgangsmÕte for fremstilling av de samme og anvendelse derav | |
| EP1853590A1 (fr) | Composés hétérocycliques liquéfiés et leur utilisation comme modulateurs de sirtuine | |
| MA27847A1 (fr) | Derives d'azetidine substituee avec 3-alkyle et 3-alcenyle. | |
| WO2006001958A3 (fr) | Modulateurs heterocycliques et carbocycliques d'amino cyclopentyle de l'activite du recepteur de la chimiokine | |
| MA33926B1 (fr) | Aminopyrimidines en tant qu'inhibiteurs de la syk | |
| NZ587251A (en) | Indole derivatives having CRTH2 antagonist activity | |
| MA33659B1 (fr) | Dihydrobenzocycloalkyl-oxyméthyl-oxazolopyrimidinones substituées, préparation et utilisation de celles-ci | |
| MA31442B1 (fr) | 3-(imidazolyl)-pyrazolo [3,4-b]pyridines | |
| WO2006094210A2 (fr) | Modulateurs de sirtuine de tetrahydroquinoxalinone | |
| WO2005105092A3 (fr) | Modulateurs de l'activité de récepteurs de chimiokines en tétrahydropyranylcyclopentylamide disubstitué en position 3,3 | |
| WO2005070133A3 (fr) | Piperidines disubstituees en 2,6, modulatrices de l'activite du recepteur de la chemokine | |
| WO2005120505A3 (fr) | Tetrahydropyranyl cyclopentyl tetrahy-dropyridopyridine modulant l'activite des recepteurs de la chimiokine | |
| WO2005110409A3 (fr) | Modulateurs tetrahydropyranyle cyclopentyle de tetrahydroisoquinoline 1 substituee et 1,1-disubstituee de l'activite des recepteurs de chimiokine | |
| PT91613B (pt) | Processo para a preparacao de derivados anti-hipertensivos de 3-piperidinil- -indazole | |
| UA95303C2 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists |